Eosinophil diversity in asthma

[en] Eosinophils are a type of granulated innate immune cells that have long been implicated in a specific type of asthma, referred to as eosinophilic asthma. Several immunotherapeutics that target and deplete eosinophils or limit their numbers are currently widely used and provide improved disease outcome in severe eosinophilic asthma. Current clinical results provide conclusive evidence of a generally detrimental role of eosinophils in asthma. Yet, a small but growing body of reports suggests that eosinophils may be more diverse than currently appreciated. In this review, we explore pre-clinical and clinical evidence that suggests the existence of eosinophil subsets with potentially distinct functional roles in asthma. We conclude by discussing state-of-the-art strategies for deciphering heterogeneity of this complex cell type, and argue this knowledge could translate into the improved personalized treatment of severe eosinophilic asthma. © 2020 Elsevier Inc.

Disciplines :

Anatomy (cytology, histology, embryology...) & physiology

Author, co-author :

Van Hulst, Glenn ; Université de Liège - ULiège > I3-Cellular and Molecular Immunology

Batugedara, Hashini Maneesha ; Université de Liège - ULiège > I3-Cellular and Molecular Immunology

Jorssen, Joseph ; Université de Liège - ULiège > I3-Cellular and Molecular Immunology

Louis, Renaud ; Université de Liège - ULiège > Département des sciences cliniques > Pneumologie - Allergologie

Bureau, Fabrice ; Université de Liège - ULiège > Vice-Recteur à la Recherche

Desmet, Christophe ; Université de Liège - ULiège > I3-Cellular and Molecular Immunology

Language :

English

Title :

Eosinophil diversity in asthma

Publication date :

2020

Journal title :

Biochemical Pharmacology

ISSN :

0006-2952

eISSN :

1873-2968

Publisher :

Elsevier Inc.

Volume :

179

Peer reviewed :

Peer Reviewed verified by ORBi

Funders :

F.R.S.-FNRS - Fonds de la Recherche Scientifique [BE]

Available on ORBi :

since 01 February 2021

Statistics

Number of views

73 (10 by ULiège)

Number of downloads

9 (9 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Lemanske, R.F. Jr., Busse, W.W., Asthma: clinical expression and molecular mechanisms. J. Allergy Clin. Immunol. 125:2 Suppl 2 (2010), S95–S102.
Lambrecht, B.N., Hammad, H., The immunology of asthma. NatureImmunology 16:1 (2015), 45–56.
Pavord, I., Sterk, P., Hargreave, F., Kips, J., Inman, M., Louis, R., et al. Clinical applications of assessment of airway inflammation using induced sputum. Eur. Respir. J. 20:37 suppl (2002), 40s–43s.
Bettiol, J., Bartsch, P., Louis, R., De Groote, D., Gevaerts, Y., Louis, E., et al. Cytokine production from peripheral whole blood in atopic and nonatopic asthmatics: relationship with blood and sputum eosinophilia and serum IgE levels. Allergy 55:12 (2000), 1134–1141.
Frick, W.E., Sedgwick, J.B., Busse, W.W., The appearance of hypodense eosinophils in antigen-dependent late phase asthma1-3. Am. Rev. Respir. Dis. 139 (1989), 1401–1406.
M.E. Rothenberg, S.P. Hogan, The eosinophil. Annual Reviews Immunology. 24 2006 pp. 147–174.
Ueki, S., Konno, Y., Takeda, M., Moritoki, Y., Hirokawa, M., Matsuwaki, Y., et al. Eosinophil extracellular trap cell death–derived DNA traps: Their presence in secretions and functional attributes. J. Allergy Clin. Immunol. 137:1 (2016), 258–267.
Ueki, S., Melo, R.C., Ghiran, I., Spencer, L.A., Dvorak, A.M., Weller, P.F., Eosinophil extracellular DNA trap cell death mediates lytic release of free secretion-competent eosinophil granules in humans. Blood 121:11 (2013), 2074–2083.
Ueki, S., Tokunaga, T., Fujieda, S., Honda, K., Hirokawa, M., Spencer, L.A., et al. Eosinophil ETosis and DNA traps: a new look at eosinophilic inflammation. Curr. Allergy Aasthma Rep., 16(8), 2016, 54.
Wenzel, S.E., Asthma phenotypes: the evolution from clinical to molecular approaches. Nat. Med., 18(5), 2012, 716.
Mori, Y., Iwasaki, H., Kohno, K., Yoshimoto, G., Kikushige, Y., Okeda, A., et al. Identification of the human eosinophil lineage-committed progenitor: revision of phenotypic definition of the human common myeloid progenitor. J. Exp. Med. 206:1 (2009), 183–193.
Kulessa, H., Frampton, J., Graf, T., GATA-1 reprograms avian myelomonocytic cell lines into eosinophils, thromboblasts, and erythroblasts. Genes Dev. 9:10 (1995), 1250–1262.
Nerlov, C., McNagny, K.M., Döderlein, G., Kowenz-Leutz, E., Graf, T., Distinct C/EBP functions are required for eosinophil lineage commitment and maturation. Genes Dev. 12:15 (1998), 2413–2423.
McNagny, K.M., Sieweke, M.H., Döderlein, G., Graf, T., Nerlov, C., Regulation of eosinophil-specific gene expression by a C/EBP–Ets complex and GATA-1. EMBO J. 17:13 (1998), 3669–3680.
Rosenberg, H.F., Dyer, K.D., Foster, P.S., Eosinophils: changing perspectives in health and disease. Nat. Rev. Immunol., 13(1), 2013, 9.
Hassani, M., Van Staveren, S., Van Grinsven, E., Bartels, M., Tesselaar, K., Leijte, G., et al. Characterization of the phenotype of human eosinophils and their progenitors in the bone marrow of healthy individuals. Haematologica, 2019.
McNagny, K., Graf, T., Making eosinophils through subtle shifts in transcription factor expression. J. Exp. Med. 195:11 (2002), F43–F47.
Mack, E.A., Pear, W.S., Transcription factor and cytokine regulation of eosinophil lineage commitment. Curr. Opin. Hematol. 27:1 (2020), 27–33.
Lopez, A.F., Begley, C.G., Williamson, D.J., Warren, D.J., Vadas, M.A., Sanderson, C.J., Murine eosinophil differentiation factor. An eosinophil-specific colony-stimulating factor with activity for human cells. J. Exp. Med. 163:5 (1986), 1085–1099.
Lopez, A., Sanderson, C., Gamble, J., Campbell, H., Young, I., Vadas, M., Recombinant human interleukin 5 is a selective activator of human eosinophil function. J. Exp. Med. 167:1 (1988), 219–224.
Rothenberg, M., Pomerantz, J.L., Owen, W., Avraham, S., Soberman, R., Austen, K., et al. Characterization of a human eosinophil proteoglycan, and augmentation of its biosynthesis and size by interleukin 3, interleukin 5, and granulocyte/macrophage colony stimulating factor. J. Biol. Chem. 263:27 (1988), 13901–13908.
Mesnil, C., Raulier, S., Paulissen, G., Xiao, X., Birrell, M.A., Pirottin, D., et al. Lung-resident eosinophils represent a distinct regulatory eosinophil subset. J. Clin. Investig. 126:9 (2016), 3279–3295.
Davoine, F., Lacy, P., Eosinophil cytokines, chemokines, and growth factors: emerging roles in immunity. Front. Immunol., 5, 2014, 570.
Hyman, P.M., Teichberg, S., Starrett, S., Vinciguerra, V., Degnan, T.J., Secretion of primary granules from developing human eosinophilic promyelocytes. Proc. Soc. Exp. Biol. Med. 159:3 (1978), 380–385.
Melo, R.C., Spencer, L.A., Perez, S.A., Neves, J.S., Bafford, S.P., Morgan, E.S., et al. Vesicle-mediated secretion of human eosinophil granule-derived major basic protein. Lab. Invest., 89(7), 2009, 769.
Acharya, K.R., Ackerman, S.J., Eosinophil granule proteins: form and function. J. Biol. Chem. 289:25 (2014), 17406–17415.
Lee, J.J., Jacobsen, E.A., Ochkur, S.I., McGarry, M.P., Condjella, R.M., Doyle, A.D., et al. Human versus mouse eosinophils:“that which we call an eosinophil, by any other name would stain as red”. J. Allergy Clin. Immunol. 130:3 (2012), 572–584.
Teixeira, M.M., Wells, T., Lukacs, N.W., Proudfoot, A., Kunkel, S.L., Williams, T.J., et al. Chemokine-induced eosinophil recruitment. Evidence of a role for endogenous eotaxin in an in vivo allergy model in mouse skin. J. Clin. Investig. 100:7 (1997), 1657–1666.
Nutku, E., Aizawa, H., Hudson, S.A., Bochner, B.S., Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood 101:12 (2003), 5014–5020.
Bochner, B.S., Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors. Clin. Exp. Allergy 39:3 (2009), 317–324.
Green, R.H., Brightling, C.E., McKenna, S., Hargadon, B., Parker, D., Bradding, P., et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360:9347 (2002), 1715–1721.
Bentley, A.M., Maestrelli, P., Saetta, M., Fabbri, L.M., Robinson, D.S., Bradley, B.L., et al. Activated T-lymphocytes and eosinophils in the bronchial mucosa in isocyanate-induced asthma. J. Allergy Clin. Immunol. 89:4 (1992), 821–829.
Bousquet, J., Chanez, P., Lacoste, J.Y., Barneon, G., Ghavanian, N., Enander, I., Venge, P., Ahlstedt, S., Simony-Lafontaine, J., Godard, P., Michel, F.B., Eosinophilic inflammation in asthma. N. Engl. J. Med. 323 (1990), 1033–1039.
De Monchy, J.G., Kauffman, H.F., Venge, P., Koëter, G.H., Jansen, H.M., Sluiter, H.J., et al. Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am. Rev. Respir. Dis. 131:3 (1985), 373–376.
Ortega, H.G., Liu, M.C., Pavord, I.D., Brusselle, G.G., FitzGerald, J.M., Chetta, A., et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 371:13 (2014), 1198–1207.
Castro, M., Zangrilli, J., Wechsler, M.E., Bateman, E.D., Brusselle, G.G., Bardin, P., et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir. Med. 3:5 (2015), 355–366.
Menzies-Gow, A., Flood-Page, P., Sehmi, R., Burman, J., Hamid, Q., Robinson, D.S., et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J. Allergy Clin. Immunol. 111:4 (2003), 714–719.
FitzGerald, J.M., Bleecker, E.R., Nair, P., Korn, S., Ohta, K., Lommatzsch, M., et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 388:10056 (2016), 2128–2141.
Laviolette, M., Gossage, D.L., Gauvreau, G., Leigh, R., Olivenstein, R., Katial, R., et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J. Allergy Clin. Immunol., 132(5), 2013 1086 96.e5.
Nair, P., Wenzel, S., Rabe, K.F., Bourdin, A., Lugogo, N.L., Kuna, P., et al. Oral glucocorticoid–sparing effect of benralizumab in severe asthma. N. Engl. J. Med. 376:25 (2017), 2448–2458.
Haldar, P., Brightling, C.E., Hargadon, B., Gupta, S., Monteiro, W., Sousa, A., et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 360:10 (2009), 973–984.
Chung, K.F., 2-year safety and efficacy results for benralizumab. Lancet Respir. Med., 7(1), 2019, 5.
Busse, W.W., Bleecker, E.R., FitzGerald, J.M., Ferguson, G.T., Barker, P., Sproule, S., et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. The Lancet Respiratory Medicine. 7:1 (2019), 46–59.
Marichal, T., Mesnil, C., Bureau, F., Homeostatic eosinophils: characteristics and functions. Front. Med. (Lausanne), 4, 2017, 101.
Qiu, Y., Nguyen, K.D., Odegaard, J.I., Cui, X., Tian, X., Locksley, R.M., et al. Eosinophils and type 2 cytokine signaling in macrophages orchestrate development of functional beige fat. Cell 157:6 (2014), 1292–1308.
Heredia, J.E., Mukundan, L., Chen, F.M., Mueller, A.A., Deo, R.C., Locksley, R.M., et al. Type 2 innate signals stimulate fibro/adipogenic progenitors to facilitate muscle regeneration. Cell 153:2 (2013), 376–388.
Yamada, T., Tani, Y., Nakanishi, H., Taguchi, R., Arita, M., Arai, H., Eosinophils promote resolution of acute peritonitis by producing proresolving mediators in mice. FASEB J. 25:2 (2011), 561–568.
Wu, D., Molofsky, A.B., Liang, H.-E., Ricardo-Gonzalez, R.R., Jouihan, H.A., Bando, J.K., et al. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science (New York, NY) 332:6026 (2011), 243–247.
Tani, Y., Isobe, Y., Imoto, Y., Segi-Nishida, E., Sugimoto, Y., Arai, H., et al. Eosinophils control the resolution of inflammation and draining lymph node hypertrophy through the proresolving mediators and CXCL13 pathway in mice. FASEB J 28:9 (2014), 4036–4043.
Rothenberg, M.E., Eosinophilia. N. Engl. J. Med. 338:22 (1998), 1592–1600.
Buhl, R., Humbert, M., Bjermer, L., Chanez, P., Heaney, L.G., Pavord, I., et al. Severe eosinophilic asthma: a roadmap to consensus. Eur. Respir. Soc., 2017.
Schleich, F.N., Chevremont, A., Paulus, V., Henket, M., Manise, M., Seidel, L., et al. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur. Respir. J. 44:1 (2014), 97–108.
Laviolette, M., Gossage, D.L., Gauvreau, G., Leigh, R., Olivenstein, R., Katial, R., et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J. Allergy Clin. Immunol., 132(5), 2013 1086 96. e5.
Pepper, A.N., Renz, H., Casale, T.B., Garn, H., Biologic therapy and novel molecular targets of severe asthma. J. Allergy Clin. Immunol. Pract. 5:4 (2017), 909–916.
Flood-Page, P., Swenson, C., Faiferman, I., Matthews, J., Williams, M., Brannick, L., et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am. J. Respir. Crit. Care Med. 176:11 (2007), 1062–1071.
Piliponsky, A.M., Pickholtz, D., Gleich, G.J., Levi-Schaffer, F., Human eosinophils induce histamine release from antigen-activated rat peritoneal mast cells: a possible role for mast cells in late-phase allergic reactions. J. Allergy Clin. Immunol. 107:6 (2001), 993–1000.
Gleich, G.J., Frigas, E., Loegering, D.A., Wassom, D.L., Steinmuller, D., Cytotoxic properties of the eosinophil major basic protein. J. Immunol. 123:6 (1979), 2925–2927.
Lehrer, R.I., Szklarek, D., Barton, A., Ganz, T., Hamann, K., Gleich, G., Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. J. Immunol. 142:12 (1989), 4428–4434.
O'Donnell, M.C., Ackerman, S., Gleich, G., Thomas, L., Activation of basophil and mast cell histamine release by eosinophil granule major basic protein. J. Exp. Med. 157:6 (1983), 1981–1991.
Ueki, S., Tokunaga, T., Melo, R.C., Saito, H., Honda, K., Fukuchi, M., et al. Charcot-Leyden crystal formation is closely associated with eosinophil extracellular trap cell death. Blood 132:20 (2018), 2183–2187.
Persson, E.K., Verstraete, K., Heyndrickx, I., Gevaert, E., Aegerter, H., Percier, J.-M., et al. Protein crystallization promotes type 2 immunity and is reversible by antibody treatment. Science (New York, NY), 364(6442), 2019, eaaw4295.
Halwani, R., Al-Muhsen, S., Al-Jahdali, H., Hamid, Q., Role of transforming growth factor–β in airway remodeling in asthma. Am. J. Respir. Cell Mol. Biol. 44:2 (2011), 127–133.
Halwani, R., Al-Muhsen, S., Hamid, Q., Airway remodeling in asthma. Curr. Opin. Pharmacol. 10:3 (2010), 236–245.
Potaczek, D.P., Miethe, S., Schindler, V., Alhamdan, F., Garn, H., Role of airway epithelial cells in the development of different asthma phenotypes. Cell Signal., 69, 2020, 109523.
Wynn, T.A., Type 2 cytokines: mechanisms and therapeutic strategies. Nat. Rev. Immunol. 15:5 (2015), 271–282.
Fulkerson, P.C., Schollaert, K.L., Bouffi, C., Rothenberg, M.E., IL-5 triggers a cooperative cytokine network that promotes eosinophil precursor maturation. J. Immunol. 193:8 (2014), 4043–4052.
Bisgaard, H., Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonists in asthma. Allergy 56:s 66 (2001), 7–11.
Günther, P., Schultze, J.L., Mind the map: technology shapes the myeloid cell space. Front. Immunol., 10, 2019, 2287.
Schyns, J., Bai, Q., Ruscitti, C., Radermecker, C., De Schepper, S., Chakarov, S., et al. Non-classical tissue monocytes and two functionally distinct populations of interstitial macrophages populate the mouse lung. Nat. Commun., 10(1), 2019, 3964.
Sabatel, C., Radermecker, C., Fievez, L., Paulissen, G., Chakarov, S., Fernandes, C., et al. Exposure to bacterial CpG DNA protects from airway allergic inflammation by expanding regulatory lung interstitial macrophages. Immunity 46:3 (2017), 457–473.
Sajti, E., Link, V.M., Ouyang, Z., Spann, N.J., Westin, E., Romanoski, C.E., et al. Transcriptomic and epigenetic mechanisms underlying myeloid diversity in the lung. Nat. Immunol., 1–11, 2020.
Abdala Valencia, H., Loffredo, L., Misharin, A., Berdnikovs, S., Phenotypic plasticity and targeting of Siglec-F high CD11c low eosinophils to the airway in a murine model of asthma. Allergy 71:2 (2016), 267–271.
Percopo, C.M., Brenner, T.A., Ma, M., Kraemer, L.S., Hakeem, R.M., Lee, J.J., et al. SiglecF+ Gr1hi eosinophils are a distinct subpopulation within the lungs of allergen-challenged mice. J. Leukoc. Biol. 101:1 (2017), 321–328.
Andreone, S., Spadaro, F., Buccione, C., Mancini, J., Tinari, A., Sestili, P., et al. IL-33 Promotes CD11b/CD18-mediated adhesion of eosinophils to cancer cells and synapse-polarized degranulation leading to tumor cell killing. Cancers., 11(11), 2019, 1664.
Yukawa, T., Kroegel, C., Evans, P., Fukuda, T., Chung, K.F., Barnes, P.J., Density heterogeneity of eosinophil leucocytes: induction of hypodense eosinophils by platelet-activating factor. Immunology 68:1 (1989), 140–143.
Fukuda, T., Dunnette, S.L., Reed, C.E., Ackerman, S.J., Peters, M.S., Gleich, G.J., Increased numbers of hypodense eosinophils in the blood of patients with bronchial asthma. Am. Rev. Respir. Dis. 132:5 (1985), 981–985.
Fukuda, T., Gleich, G.J., Heterogeneity of human eosinophils. J. Allergy Clin. Immunol. 83:2 (1989), 369–373.
Campbell, H.D., Tucker, W., Hort, Y., Martinson, M.E., Mayo, G., Clutterbuck, E.J., et al. Molecular cloning, nucleotide sequence, and expression of the gene encoding human eosinophil differentiation factor (interleukin 5). Proc. Natl. Acad. Sci. 84:19 (1987), 6629–6633.
Peters, M.S., Gleich, G.J., Dunnette, S.L., Fukuda, T., Ultrastructural study of eosinophils from patients with the hypereosinophilic syndrome: a morphological basis of hypodense eosinophils. Blood 71:3 (1988), 780–785.
Garcia-Romo, G.S., Caielli, S., Vega, B., Connolly, J., Allantaz, F., Xu, Z., et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl. Med., 3(73), 2011 73ra20-73ra20.
Chatfield, S.M., Thieblemont, N., Witko-Sarsat, V., Expanding neutrophil horizons: new concepts in inflammation. J. Innate Immun. 10:5–6 (2018), 422–431.
Morales-Camacho, R.M., Prats-Martin, C., Eosinophils with ring-shaped nuclei in a patient treated with adalimumab. Blood, 133(1), 2019, 101.
Prin, L., Charon, J., Capron, M., Gosset, P., Taelman, H., Tonnel, A., et al. Heterogeneity of human eosinophils. II. Variability of respiratory burst activity related to cell density. Clin. Exp. Immunol., 57(3), 1984, 735.
Kroegel, C., Liu, M.C., Hubbard, W.C., Lichtenstein, L.M., Bochner, B.S., Blood and bronchoalveolar eosinophils in allergic subjects after segmental antigen challenge: surface phenotype, density heterogeneity, and prostanoid production. J. Allergy Clin. Immunol. 93:4 (1994), 725–734.
Kelly, E.A., Esnault, S., Liu, L.Y., Evans, M.D., Johansson, M.W., Mathur, S., et al. Mepolizumab attenuates airway eosinophil numbers, but not their functional phenotype, in asthma. Am. J. Respir. Crit. Care Med. 196:11 (2017), 1385–1395.
Rothenberg, M.E., Owen, W., Silberstein, D.S., Woods, J., Soberman, R.J., Austen, K.F., et al. Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3. J. Clin. Investig. 81:6 (1988), 1986–1992.
Owen, W. Jr, Rothenberg, M.E., Silberstein, D., Gasson, J., Stevens, R., Austen, K., et al. Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts. J. Exp. Med. 166:1 (1987), 129–141.
Nguyen, A., Khoo, W.H., Moran, I., Croucher, P.I., Phan, T.G., Single cell RNA sequencing of rare immune cell populations. Front. Immunol., 9, 2018, 1553.
Zilionis, R., Engblom, C., Pfirschke, C., Savova, V., Zemmour, D., Saatcioglu, H.D., et al. Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species. Immunity, 50(5), 2019 1317–34. e10.
Kawashima, Y., Watanabe, E., Umeyama, T., Nakajima, D., Hattori, M., Honda, K., et al. Optimization of data-independent acquisition mass spectrometry for deep and highly sensitive proteomic analysis. Int. J. Mol. Sci., 20(23), 2019, 5932.
Miyata, J., Fukunaga, K., Kawashima, Y., Watanabe, T., Saitoh, A., Hirosaki, T., et al. Dysregulated fatty acid metabolism in nasal polyp-derived eosinophils from patients with chronic rhinosinusitis. Allergy 74:6 (2019), 1113–1124.
Wilkerson, E.M., Johansson, M.W., Hebert, A.S., Westphall, M.S., Mathur, S.K., Jarjour, N.N., et al. The peripheral blood eosinophil proteome. J. Proteome Res. 15:5 (2016), 1524–1533.
Buenrostro, J.D., Wu, B., Litzenburger, U.M., Ruff, D., Gonzales, M.L., Snyder, M.P., et al. Single-cell chromatin accessibility reveals principles of regulatory variation. Nature 523:7561 (2015), 486–490.
Tsompana, M., Buck, M.J., Chromatin accessibility: a window into the genome. Epigenet. Chromatin., 7(1), 2014, 33.